J&J Unit Loses In Ark.'s Risperdal Marketing Suit
A jury sided against a Johnson & Johnson subsidiary Tuesday in Arkansas' suit claiming it illegally promoted the antipsychotic drug Risperdal to doctors for unnecessary medical conditions at a cost to...To view the full article, register now.
Already a subscriber? Click here to view full article